Towa Pharmaceutical

Towa Pharmaceutical

4553.TPhase 2
Osaka, Japantowa-pharm.co.jp

Towa Pharmaceutical is a major Japanese generic drug manufacturer with a mission to contribute to public health by supplying stable, high-quality, and affordable generic medicines. The company has established a strong market position in Japan through its extensive portfolio of generic products and its manufacturing capabilities. Its strategic direction includes expanding its product lineup, enhancing production efficiency, and exploring opportunities in biosimilars and other advanced generic segments. As a publicly traded entity, it operates with a focus on sustainable growth and shareholder returns.

Market Cap
$338.9M
Employees
1000-5000
Focus
Biotech

4553.T · Stock Price

USD 1391.67195.00 (-12.29%)

Historical price data

AI Company Overview

Towa Pharmaceutical is a major Japanese generic drug manufacturer with a mission to contribute to public health by supplying stable, high-quality, and affordable generic medicines. The company has established a strong market position in Japan through its extensive portfolio of generic products and its manufacturing capabilities. Its strategic direction includes expanding its product lineup, enhancing production efficiency, and exploring opportunities in biosimilars and other advanced generic segments. As a publicly traded entity, it operates with a focus on sustainable growth and shareholder returns.

Technology Platform

Integrated generic drug development and manufacturing platform focused on formulation science, analytical chemistry, and bioequivalence testing to produce high-quality, affordable alternatives to off-patent branded medicines.

Pipeline Snapshot

1

1 drug in pipeline

DrugIndicationStage
Bromocriptine Mesilate + PlacebosFamilial Alzheimer Disease (FAD)Phase 1/2

Funding History

1
IPOUndisclosedUndisclosedMar 15, 2002

Opportunities

The primary growth opportunity lies in the Japanese government's policy to increase generic drug penetration to 80%, creating a larger addressable market.
Further opportunities exist in developing complex generics and biosimilars, which face less competition and may command better pricing.

Risk Factors

Key risks include sustained government-mandated price cuts (NHI price revisions), intense competition leading to margin erosion, supply chain disruptions for APIs, and regulatory hurdles in the generic approval process.

Competitive Landscape

Towa competes with other major Japanese generic firms like Sawai Pharmaceutical and Nippon Chemiphar, as well as global players. Its differentiation is based on a strong domestic manufacturing footprint, a broad product portfolio, and a reputation for reliable quality and supply in the Japanese market.

Publications
17
Patents
20
Pipeline
1

Company Info

TypeTherapeutics
Founded1951
Employees1000-5000
LocationOsaka, Japan
StagePhase 2
RevenueRevenue Generating

Trading

Ticker4553.T
ExchangeTSE

Therapeutic Areas

CardiovascularCentral Nervous SystemMetabolicGastrointestinalAnti-infective
SIMILAR COMPANIES
Otsuka Holdings
Otsuka Holdings
Pre-clinical · Tokyo
Shionogi
Shionogi
Pre-clinical · Osaka
Chugai Pharmaceutical
Chugai Pharmaceutical
Pre-clinical ·
Astellas Pharma
Astellas Pharma
Pre-clinical ·
Ono Pharmaceutical
Ono Pharmaceutical
Pre-clinical ·
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile